Emmaus Life Sciences Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
55
- Stock Symbol
-
EMMA
- Investments
-
1
- Share Price
-
$0.04
- (As of Friday Closing)
Emmaus Life Sciences General Information
Description
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Contact Information
Website
www.emmausmedical.comCorporate Office
- 21250 Hawthorne Boulevard
- Suite 800
- Torrance, CA 90503
- United States
Corporate Office
- 21250 Hawthorne Boulevard
- Suite 800
- Torrance, CA 90503
- United States
Emmaus Life Sciences Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.04 | $0.02 | $2.24M | 63.9M | 83.1K | -$0.08 |
Emmaus Life Sciences Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 39,256 | 39,199 | 45,952 | 109,607 |
| Revenue | 19,968 | 29,597 | 18,390 | 20,610 |
| EBITDA | 1,054 | 2,942 | (6,179) | (13,522) |
| Net Income | (5,256) | (3,733) | (10,625) | (15,946) |
| Total Assets | 25,939 | 35,179 | 48,225 | 56,734 |
| Total Debt | 31,441 | 32,650 | 30,818 | 22,408 |
Emmaus Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Emmaus Life Sciences Comparisons
Industry
Financing
Details
Emmaus Life Sciences Competitors (48)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals | Formerly VC-backed | Rockville, MD | ||||
| Vanda Pharmaceuticals | Formerly VC-backed | Washington, DC | ||||
| Madrigal Pharmaceuticals | Corporation | West Conshohocken, PA | ||||
| Inventiva Pharma | Corporation | Daix, France | ||||
| Galecto | Formerly VC-backed | Copenhagen, Denmark |
Emmaus Life Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Emmaus Life Sciences Patents
Emmaus Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4419651-A1 | Engineering of stratified cell sheets using mesenchymal stem cells | Pending | 21-Oct-2021 | ||
| US-20240052286-A1 | System and method of evaluating cell culture | Pending | 06-Jan-2021 | ||
| EP-4275040-A1 | System and method of evaluating cell culture | Pending | 06-Jan-2021 | ||
| EP-3790545-A1 | Methods and compositions for the treatment of sickle cell diseases and thalassemia | Inactive | 17-Jul-2019 | ||
| US-20210015778-A1 | Methods and compositions for the treatment of sickle cell diseases and thalassemia | Inactive | 17-Jul-2019 | A61K31/198 |
Emmaus Life Sciences Executive Team (12)
| Name | Title | Board Seat |
|---|---|---|
| Willis Lee | Chief Executive Officer | |
| George Carpenter IV | Executive & President | |
| George Sekulich | President, Chief Commercial Officer & Director | |
| Joseph Sherwood III | Chief Financial Officer | |
| Lan Tran | Chief Administrative Officer |
Emmaus Life Sciences Board Members (18)
| Name | Representing | Role | Since |
|---|---|---|---|
| Geoffrey Harris Ph.D | Self | Board Member | |
| Ian Zwicker | Self | Board Member | |
| John Pappajohn | Self | Board Member | |
| Michal Votruba | Self | Board Member | |
| Patrick Herguth | Self | Chief Executive Officer & Board Member |
Emmaus Life Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Emmaus Life Sciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Emmaus Life Sciences Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MYnd Analytics | 17-Jul-2019 | Other Healthcare Services |
Emmaus Life Sciences Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| EMI Holding | Pharmaceuticals | Torrance, CA |
Emmaus Life Sciences FAQs
-
When was Emmaus Life Sciences founded?
Emmaus Life Sciences was founded in 2000.
-
Who is the founder of Emmaus Life Sciences?
Yutaka Niihara MD and Daniel Kimbell JD are the founders of Emmaus Life Sciences.
-
Who is the CEO of Emmaus Life Sciences?
Willis Lee and Patrick Herguth are the CEOs of Emmaus Life Sciences.
-
Where is Emmaus Life Sciences headquartered?
Emmaus Life Sciences is headquartered in Torrance, CA.
-
What is the size of Emmaus Life Sciences?
Emmaus Life Sciences has 55 total employees.
-
What industry is Emmaus Life Sciences in?
Emmaus Life Sciences’s primary industry is Drug Discovery.
-
Is Emmaus Life Sciences a private or public company?
Emmaus Life Sciences is a Public company.
-
What is Emmaus Life Sciences’s stock symbol?
The ticker symbol for Emmaus Life Sciences is EMMA.
-
What is the current stock price of Emmaus Life Sciences?
As of 11-Oct-2024 the stock price of Emmaus Life Sciences is $0.04.
-
What is the current market cap of Emmaus Life Sciences?
The current market capitalization of Emmaus Life Sciences is $2.24M.
-
What is Emmaus Life Sciences’s current revenue?
The trailing twelve month revenue for Emmaus Life Sciences is $20M.
-
Who are Emmaus Life Sciences’s competitors?
Supernus Pharmaceuticals, Vanda Pharmaceuticals, Madrigal Pharmaceuticals, Inventiva Pharma, and Galecto are some of the 48 competitors of Emmaus Life Sciences.
-
What is Emmaus Life Sciences’s annual earnings per share (EPS)?
Emmaus Life Sciences’s EPS for 12 months was -$0.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
